CCL17 and CCL22/CCR4 signaling is a strong candidate for novel targeted therapy against nasal natural killer/T-cell lymphoma.

DOI IR PDF Web Site Web Site PubMed View 1 Remaining Hide 11 Citations 44 References Open Access

Description

http://link.springer.com/article/10.1007%2Fs00262-015-1675-7 | http://link.springer.com/article/10.1007%2Fs00262-015-1675-7

Journal

Cancer Immunology, Immunotherapy

Cancer Immunology, Immunotherapy 64 (6), 697-705, 2015-06-01

Springer Science and Business Media LLC

Citations (11)*help

See more

References(44)*help

See more

Related Projects

See more

Keywords

Details 詳細情報について

CRID

1050581246231053824
NII Article ID

120005774022
DOI

10.1007/s00262-015-1675-7
ISSN

14320851

03407004
PubMed

25754123
Web Site

https://asahikawa-med.repo.nii.ac.jp/records/5500

http://link.springer.com/content/pdf/10.1007/s00262-015-1675-7.pdf

http://link.springer.com/article/10.1007/s00262-015-1675-7/fulltext.html

http://link.springer.com/content/pdf/10.1007/s00262-015-1675-7
Text Lang

en
Article Type

journal article
Data Source
- IRDB
- Crossref
- CiNii Articles
- KAKEN
- OpenAIRE

Export

Report a problem

Back to top